Danlaw Technologies India Ltd
532329Danlaw Technologies India Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: profits are rising, but only 29% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (8 weeks in) while the P/E sits at the 79th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit −30.7% year on year, and 29% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Danlaw Technologies India Ltd trades at ₹1,198, in a confirmed uptrend and 8 weeks into that stage. That is +36.5% against its own 200-day average. It sits at 100% of a 52-week range of ₹746 to ₹1,198. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 8 of stage 2, confirmed. At ₹1,198 it trades +36.5% versus its 200-day average and sits at 100% of its 52-week range (₹746–₹1,198).
Against the market, two honest reads. Cumulative: over the last 2 months the stock moved +61% while the NIFTY 500 moved +5% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Danlaw Technologies India Ltd trades at 115.0× P/E, at the pricey end of its own range (79th percentile). Its long-run median P/E is 56.8×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 115.0× is at the pricey end of its own range (79th percentile), against a long-run median of 56.8× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Danlaw Technologies India Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 9 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +23.2% | +30.4% | +56.5% | +29.8% |
| Profit | +100.0% | — | — | — |
| EPS | +1,216.7% | — | — | +24.5% |
4-Factor Sector Score
44.9/100 — rank 60 of 64 in IT - Software · 32% evidence confidence · provisional, ranked below fully-evidenced peers
Danlaw Technologies India Ltd scores 44.9 out of 100 against the 64 companies it is compared with in IT - Software, ranking 60. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 16.3 + 7.7 + 8.7 + 12.2 = 44.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Danlaw Technologies India Ltd reported ₹38.0 Cr of revenue in the Sep 22 quarter, +24.5% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 29.8% a year. The last full year, FY22, came in at ₹122 Cr. The last four reported quarters add to ₹138 Cr.
FY22 revenue came in at ₹122 Cr (+23.2% on the year), capping 10 years at 29.8% compound. The latest quarter (Sep 22) printed ₹38.0 Cr, +24.5% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +12.4% growth against the decade's 29.8% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +10.9% over the last 4 quarters against +49.7%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Danlaw Technologies India Ltd's operating margin is 8.9% in the Sep 22 quarter, +1.0 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −8.0% to 18.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 8.9%, +1.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −8.0%–18.0%.
Why the margin moved: operating margin went +1.0 pp year on year while gross margin went −1.8 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Danlaw Technologies India Ltd earned ₹1.2 Cr of net profit in the Sep 22 quarter, −30.7% year on year. Full-year FY22 profit was ₹4.0 Cr. That is 3.3% of the quarter's revenue. The same quarter a year earlier earned ₹1.8 Cr. 6 of the last 12 reported quarters were loss-making.
Sep 22 profit was ₹1.2 Cr, −30.7% year on year. On the full year, FY22 printed ₹4.0 Cr (+100.0%).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 29% of Danlaw Technologies India Ltd's reported profit arrived as operating cash — a gap worth watching. In FY22 that was ₹6.0 Cr of operating cash against ₹4.0 Cr of profit. After ₹5.0 Cr of capital spending, ₹1.0 Cr was left as free cash.
FY22: operating cash of ₹6.0 Cr against reported profit of ₹4.0 Cr, leaving free cash of ₹1.0 Cr after ₹5.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 29% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 29%: the cash cycle tightened 115 days between FY17 and FY22 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: the bigger cash user is investment — capital spending ran 2.6× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Danlaw Technologies India Ltd's cash conversion cycle runs 105 days in FY22, down from 220 days in FY17. Capital spending ran ₹29.0 Cr over the last 3 years. At FY22 sales of ₹122 Cr each day of that cycle holds about ₹0.3 Cr, so roughly ₹35.0 Cr sits inside the business at any moment.
FY22: debtors at 55 days, inventory at 130 days — roughly 4.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 105 days, tighter than FY17's 220.
The full loop: cash goes out to suppliers and production on day 0; stock waits 130 days to sell; customers pay about 55 days after that; and suppliers themselves are paid at 80 days — netting out to the 105-day cycle.
In money terms: at FY22 sales of ₹122 Cr, each day of the cycle holds about ₹0.3 Cr — so the 105-day loop keeps roughly ₹35.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹29.0 Cr over the last 3 fiscal years against ₹11.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY22) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Danlaw Technologies India Ltd earns a ROCE of 8% in FY22. That is up from a trough of −20% in FY20. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 3.3% net margin on 1.37× asset turns.
FY22 ROCE is 8%, recovered from a FY20 trough of −20% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY22): 3.3% net margin × 1.37× asset turns × 3.87× balance-sheet leverage ≈ 17.5% on equity. Margin does its share; leverage is a meaningful part of the equation.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Danlaw Technologies India Ltd carries ₹12.0 Cr of borrowings against ₹23.0 Cr of equity in FY22, a debt-to-equity of 0.52. Operating profit covers the interest bill 3×. Over 5 years borrowings went from ₹0.0 Cr to ₹12.0 Cr. Capital spending ran ₹29.0 Cr across the last 3 of those years.
FY22: borrowings of ₹12.0 Cr against equity of ₹23.0 Cr — a debt-to-equity of 0.52. Operating profit covers the interest bill 3×. Over 5 years borrowings went from ₹0.0 Cr to ₹12.0 Cr while capital spending ran ₹29.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Danlaw Technologies India Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved +0.0 points over the same window, to 0.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +0.0 points over 8 quarters to 61.9%; Foreign institutions: +0.0 points over 8 quarters to 0.0%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Danlaw Technologies India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Coforge LtdCOFORGE | 76.1/100Favorable setup100% evidence | BREAKING OUT | 30.2/35 Revenue 35.7% · PAT 66.5% · OPM change 3 pp 100% evidence | 15.7/25 ROCE 23.5% · OPM 19% 100% evidence | 12.7/20 P/E 41× · PEG 0.57 100% evidence | 17.5/20 RS sector 8.3% · RS bench 12.6% · 1Y 4.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.2 + 15.7 + 12.7 + 17.5 = 76.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Silver Touch Technologies LtdSILVERTUC | 71.8/100Favorable setup93% evidence | LEADER | 30.5/35 Revenue 21.1% · PAT 86.4% · OPM change 8 pp 100% evidence | 17.4/25 ROCE 29.8% · OPM 22% 100% evidence | 10.2/20 P/E 59.6× · PEG 1.11 65% evidence | 13.7/20 RS sector 44% · RS bench 52.8% · 1Y 163.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.5 + 17.4 + 10.2 + 13.7 = 71.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3NINtec Systems LtdNINSYS | 68.0/100Favorable setup76% evidence | LEADER | 20.8/35 Revenue 21.7% · PAT 21.6% · OPM change 8.1 pp 83% evidence | 22.0/25 ROCE 55% · OPM 30.1% 95% evidence | 9.2/20 P/E 42.9× · PEG — 15% evidence | 16.0/20 RS sector 37.4% · RS bench 43.6% · 1Y 71.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 22 + 9.2 + 16 = 68 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4ASM Technologies Ltd526433 | 68.0/100Favorable setup69% evidence | TURNING | 28.1/35 Revenue 67.8% · PAT 89.5% · OPM change 2 pp 95% evidence | 16.3/25 ROCE 27% · OPM 23% 76% evidence | 8.8/20 P/E 96.5× · PEG — 15% evidence | 14.8/20 RS sector 5.7% · RS bench 39.5% · 1Y 78.7%10 of 10 weeks ahead 70% evidence |
| Exact sum: 28.1 + 16.3 + 8.8 + 14.8 = 68 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Sasken Technologies LtdSASKEN | 66.9/100Favorable setup100% evidence | LEADER | 30.9/35 Revenue 67.8% · PAT 67.4% · OPM change 4 pp 100% evidence | 8.0/25 ROCE 9.9% · OPM 9% 100% evidence | 9.6/20 P/E 39.6× · PEG 0.68 100% evidence | 18.4/20 RS sector 18.7% · RS bench 24.2% · 1Y 31.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.9 + 8 + 9.6 + 18.4 = 66.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6InfoBeans Technologies LtdINFOBEAN | 66.9/100Favorable setup81% evidence | ASLEEP | 26.8/35 Revenue 35.5% · PAT 60.4% · OPM change 0 pp 95% evidence | 16.8/25 ROCE 29.2% · OPM 21% 95% evidence | 9.5/20 P/E 19.2× · PEG — 50% evidence | 13.8/20 RS sector 17.4% · RS bench -1.4% · 1Y 22.3%4 of 10 weeks ahead 70% evidence |
| Exact sum: 26.8 + 16.8 + 9.5 + 13.8 = 66.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7Sahana Systems LtdSAHANA | 64.7/100Mixed-positive evidence70% evidence | BASING | 21.7/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 19.6/25 ROCE 39.8% · OPM 29% 95% evidence | 14.5/20 P/E 12.7× · PEG — 50% evidence | 8.9/20 RS sector -19% · RS bench -1.3% · 1Y -34.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 19.6 + 14.5 + 8.9 = 64.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Tech Mahindra LtdTECHM | 63.5/100Mixed-positive evidence94% evidence | TURNING | 21.2/35 Revenue 10.9% · PAT 14.3% · OPM change 3 pp 100% evidence | 16.3/25 ROCE 23.1% · OPM 17% 100% evidence | 10.9/20 P/E 30.1× · PEG 0.76 100% evidence | 15.1/20 RS sector 14.8% · RS bench 6.9% · 1Y 13.6%5 of 11 weeks ahead 70% evidence |
| Exact sum: 21.2 + 16.3 + 10.9 + 15.1 = 63.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Datamatics Global Services LtdDATAMATICS | 63.1/100Mixed-positive evidence94% evidence | TURNING | 21.3/35 Revenue 13.1% · PAT 1.9% · OPM change 4 pp 100% evidence | 16.1/25 ROCE 20.8% · OPM 20% 100% evidence | 11.3/20 P/E 20.2× · PEG 0.58 100% evidence | 14.4/20 RS sector 9.6% · RS bench 3.9% · 1Y -13.9%6 of 10 weeks ahead 70% evidence |
| Exact sum: 21.3 + 16.1 + 11.3 + 14.4 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Hypersoft Technologies Ltd539724 | 63.1/100Mixed-positive evidence61% evidence | LEADER | 25.6/35 Revenue 100% · PAT 100% · OPM change 2.9 pp 71% evidence | 12.0/25 ROCE 20.6% · OPM 14% 76% evidence | 8.6/20 P/E 421× · PEG — 15% evidence | 16.9/20 RS sector 65% · RS bench 74.2% · 1Y 230.2%12 of 12 weeks ahead 70% evidence |
| Exact sum: 25.6 + 12 + 8.6 + 16.9 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Cigniti Technologies LtdCIGNITITEC | 62.6/100Mixed-positive evidence79% evidence | 23.5/35 Revenue 14% · PAT 96.1% · OPM change 2 pp 56% evidence | 16.2/25 ROCE 34.1% · OPM 18% 75% evidence | 16.0/20 P/E 11.4× · PEG 0.61 100% evidence | 6.9/20 RS sector -9.5% · RS bench -15% · 1Y -21.7%0 of 12 weeks ahead to 2026-05-17 100% evidence | |
| Exact sum: 23.5 + 16.2 + 16 + 6.9 = 62.6 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -9.5% and the one-year return is -21.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Softtech Engineers LtdSOFTTECH | 60.9/100Mixed-positive evidence76% evidence | FADING | 27.9/35 Revenue 39.5% · PAT 100% · OPM change 6.2 pp 83% evidence | 11.7/25 ROCE 6.2% · OPM 21.4% 95% evidence | 8.7/20 P/E 118× · PEG — 15% evidence | 12.6/20 RS sector 10.5% · RS bench 15.3% · 1Y 15.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 27.9 + 11.7 + 8.7 + 12.6 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13BLS E-Services LtdBLSE | 58.6/100Mixed-positive evidence75% evidence | LEADER | 19.2/35 Revenue 71.2% · PAT 9.4% · OPM change 0 pp 95% evidence | 10.7/25 ROCE 17% · OPM 7% 76% evidence | 9.0/20 P/E 48.6× · PEG — 15% evidence | 19.7/20 RS sector 47% · RS bench 53.4% · 1Y 69.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 10.7 + 9 + 19.7 = 58.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14String Metaverse Ltd534535 | 58.0/100Mixed-positive evidence78% evidence | BASING | 26.2/35 Revenue 100% · PAT 100% · OPM change 0 pp 83% evidence | 15.4/25 ROCE 41.6% · OPM 10% 76% evidence | 14.7/20 P/E 8.2× · PEG — 50% evidence | 1.7/20 RS sector -60.9% · RS bench -52.1% · 1Y -75.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 26.2 + 15.4 + 14.7 + 1.7 = 58 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -60.9% and the one-year return is -75.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 15TAC Infosec LtdTAC | 57.9/100Thin evidence · provisional54% evidence | TURNING | 21.5/35 Revenue — · PAT — · OPM change 1.6 pp 39% evidence | 20.6/25 ROCE 38.1% · OPM 48.2% 95% evidence | 9.5/20 P/E 39× · PEG — 15% evidence | 6.3/20 RS sector -13.2% · RS bench -12% · 1Y 18.8%1 of 10 weeks ahead 70% evidence |
| Exact sum: 21.5 + 20.6 + 9.5 + 6.3 = 57.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Ksolves India LtdKSOLVES | 57.2/100Mixed-positive evidence87% evidence | ASLEEP | 17.9/35 Revenue 16% · PAT 16.7% · OPM change 3.9 pp 95% evidence | 20.5/25 ROCE 131% · OPM 30.3% 95% evidence | 13.6/20 P/E 17.9× · PEG — 50% evidence | 5.2/20 RS sector -12.5% · RS bench -8.4% · 1Y -11.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 20.5 + 13.6 + 5.2 = 57.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Infosys LtdINFY | 57.1/100Mixed-positive evidence82% evidence | BASING | 18.4/35 Revenue 11.2% · PAT 11.1% · OPM change 0 pp 95% evidence | 20.1/25 ROCE 40% · OPM 24% 76% evidence | 13.9/20 P/E 15.3× · PEG — 50% evidence | 4.7/20 RS sector -19.8% · RS bench -16.1% · 1Y -20%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 20.1 + 13.9 + 4.7 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Subex LtdSUBEXLTD | 56.7/100Mixed-positive evidence65% evidence | TURNING | 24.5/35 Revenue 2.8% · PAT 100% · OPM change 13 pp 95% evidence | 10.4/25 ROCE 12.8% · OPM 19% 95% evidence | 9.9/20 P/E 23.9× · PEG — 15% evidence | 11.9/20 RS sector — · RS bench 19.3% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 24.5 + 10.4 + 9.9 + 11.9 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19R Systems International LtdRSYSTEMS | 55.6/100Mixed-positive evidence100% evidence | ASLEEP | 19.3/35 Revenue 24.1% · PAT -1% · OPM change 3 pp 100% evidence | 16.6/25 ROCE 19.5% · OPM 18% 100% evidence | 18.2/20 P/E 13.9× · PEG 0.26 100% evidence | 1.5/20 RS sector -31.2% · RS bench -28.6% · 1Y -41%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 16.6 + 18.2 + 1.5 = 55.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Xchanging Solutions LtdXCHANGING | 55.2/100Mixed-positive evidence77% evidence | ASLEEP | 21.1/35 Revenue 9.7% · PAT 18% · OPM change 3 pp 83% evidence | 15.4/25 ROCE 18% · OPM 37% 95% evidence | 13.4/20 P/E 12.6× · PEG — 50% evidence | 5.3/20 RS sector -24.4% · RS bench -10.8% · 1Y -23.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 21.1 + 15.4 + 13.4 + 5.3 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21RNIT AI Solutions LtdAUTOPALIND | 54.4/100Thin evidence · provisional51% evidence | 20.5/35 Revenue 59.8% · PAT 66.7% · OPM change 5.1 pp 83% evidence | 14.6/25 ROCE 20.2% · OPM 40.2% 76% evidence | 9.3/20 P/E 39.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 9 weeks ahead 0% evidence | |
| Exact sum: 20.5 + 14.6 + 9.3 + 10 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22LTM LtdLTM | 54.2/100Mixed-positive evidence100% evidence | TURNING | 17.4/35 Revenue 13.9% · PAT 10% · OPM change 1 pp 100% evidence | 17.8/25 ROCE 29.6% · OPM 18% 100% evidence | 11.2/20 P/E 24.6× · PEG 1.18 100% evidence | 7.8/20 RS sector -12.4% · RS bench -8.5% · 1Y -7.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 17.8 + 11.2 + 7.8 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23AvenuesAI LtdCCAVENUE | 54.2/100Mixed-positive evidence83% evidence | BREAKING OUT | 20.3/35 Revenue 100% · PAT 25.5% · OPM change -2.3 pp 88% evidence | 8.3/25 ROCE 7.7% · OPM 3.7% 100% evidence | 14.8/20 P/E 21.3× · PEG 0.37 65% evidence | 10.8/20 RS sector -2.2% · RS bench 3.2% · 1Y 11.6%6 of 11 weeks ahead 70% evidence |
| Exact sum: 20.3 + 8.3 + 14.8 + 10.8 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Tanla Platforms LtdTANLA | 53.7/100Mixed-positive evidence94% evidence | TURNING | 14.7/35 Revenue 13.2% · PAT 9.9% · OPM change 0 pp 100% evidence | 16.6/25 ROCE 26.3% · OPM 16% 100% evidence | 12.9/20 P/E 15.3× · PEG 1.21 100% evidence | 9.5/20 RS sector -12% · RS bench 8.9% · 1Y -0.5%9 of 10 weeks ahead 70% evidence |
| Exact sum: 14.7 + 16.6 + 12.9 + 9.5 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25HCL Technologies LtdHCLTECH | 53.7/100Mixed-positive evidence76% evidence | TURNING | 12.7/35 Revenue 12.6% · PAT 2.6% · OPM change 0 pp 95% evidence | 19.1/25 ROCE 30.4% · OPM 20% 76% evidence | 9.5/20 P/E 20.3× · PEG — 50% evidence | 12.4/20 RS sector 9.9% · RS bench -6.5% · 1Y -6.6%2 of 10 weeks ahead 70% evidence |
| Exact sum: 12.7 + 19.1 + 9.5 + 12.4 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Saksoft LtdSAKSOFT | 53.3/100Mixed-positive evidence94% evidence | BREAKING OUT | 18.4/35 Revenue 8.2% · PAT 13% · OPM change 0 pp 100% evidence | 15.7/25 ROCE 25.5% · OPM 18% 100% evidence | 13.2/20 P/E 16.3× · PEG 0.6 100% evidence | 6.0/20 RS sector -21.2% · RS bench -6.1% · 1Y -19.9%7 of 11 weeks ahead 70% evidence |
| Exact sum: 18.4 + 15.7 + 13.2 + 6 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Seshaasai Technologies LtdSTYL | 52.5/100Mixed-positive evidence73% evidence | TURNING | 13.0/35 Revenue 6.7% · PAT 20.6% · OPM change 0 pp 100% evidence | 17.0/25 ROCE 27.7% · OPM 23% 100% evidence | 12.5/20 P/E 25× · PEG 0.81 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 10 weeks ahead 0% evidence |
| Exact sum: 13 + 17 + 12.5 + 10 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Tata Consultancy Services LtdTCS | 52.4/100Mixed-positive evidence94% evidence | ASLEEP | 10.7/35 Revenue 7.7% · PAT 1.1% · OPM change -1 pp 100% evidence | 22.4/25 ROCE 63% · OPM 26% 100% evidence | 11.8/20 P/E 16.5× · PEG 1.85 100% evidence | 7.5/20 RS sector -4.6% · RS bench -12.5% · 1Y -18.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 10.7 + 22.4 + 11.8 + 7.5 = 52.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Dynacons Systems & Solutions LtdDSSL | 52.0/100Mixed-positive evidence83% evidence | FADING | 15.8/35 Revenue 12.4% · PAT 19.4% · OPM change 0 pp 83% evidence | 16.9/25 ROCE 29.8% · OPM 9% 95% evidence | 7.8/20 P/E 18.4× · PEG — 50% evidence | 11.5/20 RS sector 6.8% · RS bench 12.2% · 1Y 23.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 16.9 + 7.8 + 11.5 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Expleo Solutions LtdEXPLEOSOL | 51.4/100Mixed-positive evidence77% evidence | ASLEEP | 15.3/35 Revenue 8.1% · PAT 20.4% · OPM change -1 pp 83% evidence | 15.9/25 ROCE 24.2% · OPM 15% 95% evidence | 13.8/20 P/E 9.8× · PEG — 50% evidence | 6.4/20 RS sector -13.4% · RS bench -9.8% · 1Y -28.2%4 of 10 weeks ahead 70% evidence |
| Exact sum: 15.3 + 15.9 + 13.8 + 6.4 = 51.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 31IZMO LtdIZMO | 50.9/100Mixed-positive evidence77% evidence | TURNING | 15.9/35 Revenue 26.1% · PAT -2% · OPM change -5 pp 83% evidence | 12.6/25 ROCE 12.6% · OPM 14% 95% evidence | 6.6/20 P/E 31× · PEG — 50% evidence | 15.8/20 RS sector 28.9% · RS bench 15.7% · 1Y 172.8%8 of 10 weeks ahead 70% evidence |
| Exact sum: 15.9 + 12.6 + 6.6 + 15.8 = 50.9 · Decision use: Price leads the evidence: RS versus the benchmark is 15.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 32Birlasoft LtdBSOFT | 50.8/100Mixed-positive evidence100% evidence | BASING | 19.9/35 Revenue 1.4% · PAT 21.1% · OPM change 4 pp 100% evidence | 13.1/25 ROCE 21.2% · OPM 16% 100% evidence | 14.4/20 P/E 14.9× · PEG 0.62 100% evidence | 3.4/20 RS sector -19.2% · RS bench -15.2% · 1Y -20.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 13.1 + 14.4 + 3.4 = 50.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33Capillary Technologies India LtdCAPILLARY | 50.5/100Mixed-positive evidence63% evidence | ASLEEP | 27.5/35 Revenue 27.8% · PAT 135.8% · OPM change 5.8 pp 100% evidence | 4.1/25 ROCE 3.4% · OPM 15.7% 100% evidence | 8.9/20 P/E 87.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 27.5 + 4.1 + 8.9 + 10 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34Mastek LtdMASTEK | 50.2/100Mixed-positive evidence82% evidence | TURNING | 14.2/35 Revenue 6% · PAT 5% · OPM change 0 pp 95% evidence | 13.8/25 ROCE 18% · OPM 15% 76% evidence | 12.7/20 P/E 13× · PEG — 50% evidence | 9.5/20 RS sector -10.5% · RS bench -6.9% · 1Y -25.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 13.8 + 12.7 + 9.5 = 50.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Wipro LtdWIPRO | 50.0/100Mixed-positive evidence94% evidence | ASLEEP | 13.4/35 Revenue 6.4% · PAT -1.7% · OPM change 0 pp 100% evidence | 15.1/25 ROCE 17.8% · OPM 19% 100% evidence | 13.1/20 P/E 14× · PEG 1.4 100% evidence | 8.4/20 RS sector -1.9% · RS bench -17.2% · 1Y -22.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13.4 + 15.1 + 13.1 + 8.4 = 50 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 36Blue Cloud Softech Solutions Ltd539607 | 49.3/100Mixed-negative evidence65% evidence | ASLEEP | 20.3/35 Revenue 25.7% · PAT 39.5% · OPM change 8 pp 83% evidence | 10.9/25 ROCE 14.2% · OPM 17% 76% evidence | 9.6/20 P/E 30.1× · PEG — 15% evidence | 8.5/20 RS sector -1.9% · RS bench -14.2% · 1Y -41.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.3 + 10.9 + 9.6 + 8.5 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Mphasis LtdMPHASIS | 48.8/100Mixed-negative evidence94% evidence | TURNING | 15.5/35 Revenue 13.7% · PAT 9.9% · OPM change -1 pp 100% evidence | 17.4/25 ROCE 22.1% · OPM 18% 100% evidence | 5.6/20 P/E 24.4× · PEG 2.19 100% evidence | 10.3/20 RS sector 0% · RS bench -4.8% · 1Y -10.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 15.5 + 17.4 + 5.6 + 10.3 = 48.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 38TechNVision Ventures LtdTECHNVISN | 48.3/100Mixed-negative evidence62% evidence | ASLEEP | 16.9/35 Revenue 18.2% · PAT 90.9% · OPM change -5.7 pp 62% evidence | 8.9/25 ROCE 12.9% · OPM -4.1% 95% evidence | 8.5/20 P/E 16333× · PEG — 15% evidence | 14.0/20 RS sector 32.1% · RS bench -2% · 1Y 41.8%0 of 7 weeks ahead 70% evidence |
| Exact sum: 16.9 + 8.9 + 8.5 + 14 = 48.3 · Decision use: Price leads the evidence: RS versus the benchmark is -2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 39Hexaware Technologies LtdHEXT | 48.2/100Mixed-negative evidence94% evidence | TURNING | 14.5/35 Revenue 13% · PAT 1.2% · OPM change 4 pp 100% evidence | 17.7/25 ROCE 30.1% · OPM 16% 100% evidence | 10.5/20 P/E 24.4× · PEG 0.81 100% evidence | 5.5/20 RS sector -21.4% · RS bench -9.9% · 1Y -18.7%7 of 10 weeks ahead 70% evidence |
| Exact sum: 14.5 + 17.7 + 10.5 + 5.5 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40Sonata Software LtdSONATSOFTW | 47.2/100Mixed-negative evidence97% evidence | FADING | 9.6/35 Revenue 4% · PAT 7.9% · OPM change 0 pp 95% evidence | 13.6/25 ROCE 30.7% · OPM 5% 95% evidence | 13.0/20 P/E 17.6× · PEG 0.81 100% evidence | 11.0/20 RS sector -4.7% · RS bench -0.9% · 1Y -12.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 9.6 + 13.6 + 13 + 11 = 47.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 41Zensar Technologies LtdZENSARTECH | 46.7/100Mixed-negative evidence100% evidence | ASLEEP | 16.0/35 Revenue 8% · PAT 15.3% · OPM change 0 pp 100% evidence | 13.8/25 ROCE 22.8% · OPM 15% 100% evidence | 13.3/20 P/E 14.3× · PEG 1.11 100% evidence | 3.6/20 RS sector -26.3% · RS bench -23.3% · 1Y -37%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 13.8 + 13.3 + 3.6 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 42Unicommerce eSolutions LtdUNIECOM | 46.6/100Mixed-negative evidence70% evidence | ASLEEP | 15.1/35 Revenue 51.6% · PAT 16.1% · OPM change -4.8 pp 83% evidence | 17.1/25 ROCE 21.1% · OPM 13.4% 95% evidence | 9.1/20 P/E 46.3× · PEG — 15% evidence | 5.3/20 RS sector -14.5% · RS bench -24.9% · 1Y -29.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 15.1 + 17.1 + 9.1 + 5.3 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 43XT Global Infotech LtdXTGLOBAL | 46.6/100Mixed-negative evidence61% evidence | 18.8/35 Revenue 85.4% · PAT 29.4% · OPM change -6.6 pp 53% evidence | 9.3/25 ROCE 7.5% · OPM 9.5% 71% evidence | 9.5/20 P/E 40.8× · PEG — 50% evidence | 9.0/20 RS sector -1.1% · RS bench -12.7% · 1Y -16.6%2 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 18.8 + 9.3 + 9.5 + 9 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 44Excelsoft Technologies LtdEXCELSOFT | 44.9/100Mixed-negative evidence60% evidence | ASLEEP | 12.5/35 Revenue 26.8% · PAT 4.2% · OPM change -1.8 pp 95% evidence | 12.2/25 ROCE 13.6% · OPM 16.3% 95% evidence | 10.2/20 P/E 19.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 12.5 + 12.2 + 10.2 + 10 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 45Mindteck (India) LtdMINDTECK | 44.3/100Mixed-negative evidence77% evidence | ASLEEP | 14.8/35 Revenue -4% · PAT 10.3% · OPM change 2 pp 83% evidence | 10.9/25 ROCE 15.1% · OPM 10% 95% evidence | 11.7/20 P/E 18× · PEG — 50% evidence | 6.9/20 RS sector -10.1% · RS bench -11.7% · 1Y -5.7%3 of 10 weeks ahead 70% evidence |
| Exact sum: 14.8 + 10.9 + 11.7 + 6.9 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 46Magellanic Cloud LtdMCLOUD | 44.3/100Mixed-negative evidence77% evidence | FADING | 13.3/35 Revenue 17.1% · PAT 11.7% · OPM change -3 pp 83% evidence | 15.6/25 ROCE 19.8% · OPM 26% 95% evidence | 11.9/20 P/E 15.1× · PEG — 50% evidence | 3.5/20 RS sector -54.5% · RS bench -25.6% · 1Y -64.6%5 of 11 weeks ahead 70% evidence |
| Exact sum: 13.3 + 15.6 + 11.9 + 3.5 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 47Allied Digital Services LtdADSL | 40.6/100Mixed-negative evidence74% evidence | ASLEEP | 19.4/35 Revenue 19.9% · PAT 25.8% · OPM change 0 pp 95% evidence | 6.4/25 ROCE 7.3% · OPM 9% 95% evidence | 10.5/20 P/E 16.7× · PEG — 15% evidence | 4.3/20 RS sector -29.8% · RS bench -20% · 1Y -27.4%4 of 10 weeks ahead 70% evidence |
| Exact sum: 19.4 + 6.4 + 10.5 + 4.3 = 40.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 48Innovana Thinklabs LtdINNOVANA | 38.9/100Mixed-negative evidence77% evidence | ASLEEP | 10.2/35 Revenue 27.9% · PAT -18.2% · OPM change -46.5 pp 83% evidence | 10.2/25 ROCE 16.4% · OPM 9.7% 95% evidence | 9.7/20 P/E 17.9× · PEG — 50% evidence | 8.8/20 RS sector -0.4% · RS bench -21.6% · 1Y -34.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 10.2 + 10.2 + 9.7 + 8.8 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4963 Moons Technologies Ltd63MOONS | 38.4/100Mixed-negative evidence62% evidence | BREAKING OUT | 16.7/35 Revenue 100% · PAT -17% · OPM change 397 pp 83% evidence | 3.4/25 ROCE -3.7% · OPM -57% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.3/20 RS sector -22.4% · RS bench 15.5% · 1Y -13.3%8 of 11 weeks ahead 70% evidence |
| Exact sum: 16.7 + 3.4 + 10 + 8.3 = 38.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 50Kellton Tech Solutions LtdKELLTONTEC | 36.8/100Mixed-negative evidence81% evidence | ASLEEP | 10.4/35 Revenue 9.5% · PAT 9.6% · OPM change -1 pp 95% evidence | 9.8/25 ROCE 15% · OPM 11% 95% evidence | 11.5/20 P/E 8.2× · PEG — 50% evidence | 5.1/20 RS sector -18.8% · RS bench -25.4% · 1Y -49.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 10.4 + 9.8 + 11.5 + 5.1 = 36.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 51Aurionpro Solutions LtdAURIONPRO | 36.5/100Mixed-negative evidence93% evidence | ASLEEP | 13.6/35 Revenue 14.8% · PAT 5.1% · OPM change -3 pp 100% evidence | 10.8/25 ROCE 16.3% · OPM 17% 100% evidence | 10.0/20 P/E 19.2× · PEG 1.39 65% evidence | 2.1/20 RS sector -31% · RS bench -28.2% · 1Y -46.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 10.8 + 10 + 2.1 = 36.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 52Moschip Technologies LtdMOSCHIP | 29.8/100Adverse evidence87% evidence | ASLEEP | 8.0/35 Revenue 8.4% · PAT -33.6% · OPM change -3.9 pp 100% evidence | 7.0/25 ROCE 11% · OPM 8.2% 100% evidence | 3.6/20 P/E 126× · PEG 5.04 65% evidence | 11.2/20 RS sector 1.9% · RS bench -4.1% · 1Y 22.9%8 of 10 weeks ahead 70% evidence |
| Exact sum: 8 + 7 + 3.6 + 11.2 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 53Quick Heal Technologies LtdQUICKHEAL | 19.0/100Adverse evidence69% evidence | ASLEEP | 6.2/35 Revenue -6.6% · PAT -80% · OPM change -22.1 pp 71% evidence | 1.7/25 ROCE -4.7% · OPM -39% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.1/20 RS sector -35.1% · RS bench -33% · 1Y -50.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 6.2 + 1.7 + 10 + 1.1 = 19 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 54Covance Softsol Ltd544361 | 67.1/100Thin evidence · provisional49% evidence | 25.8/35 Revenue 43.5% · PAT 100% · OPM change 19.7 pp 62% evidence | 17.9/25 ROCE 31.4% · OPM 23.1% 76% evidence | 11.2/20 P/E 12.9× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 48.4% · 1Y — 25% evidence | |
| Exact sum: 25.8 + 17.9 + 11.2 + 12.2 = 67.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Meta Infotech LtdMETA | 54.4/100Thin evidence · provisional21% evidence | 17.0/35 Revenue — · PAT — · OPM change -2 pp 10% evidence | 16.3/25 ROCE 51.1% · OPM 8% 57% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -49.5%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 17 + 16.3 + 11.1 + 10 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 56Exato Technologies Ltd544626 | 52.7/100Thin evidence · provisional33% evidence | 17.0/35 Revenue — · PAT — · OPM change -3.9 pp 32% evidence | 16.2/25 ROCE 26.8% · OPM 10.4% 76% evidence | 9.5/20 P/E 39.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 17 + 16.2 + 9.5 + 10 = 52.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Kody Technolab LtdKODYTECH | 52.6/100Thin evidence · provisional48% evidence | TURNING | 15.2/35 Revenue — · PAT — · OPM change -5 pp 19% evidence | 13.0/25 ROCE 16.8% · OPM 29% 95% evidence | 8.7/20 P/E 116× · PEG — 15% evidence | 15.7/20 RS sector 10.3% · RS bench 56.2% · 1Y 76.9%7 of 10 weeks ahead 70% evidence |
| Exact sum: 15.2 + 13 + 8.7 + 15.7 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Unified Data- Tech Solutions LtdUNIFIED | 52.6/100Thin evidence · provisional22% evidence | 15.8/35 Revenue — · PAT — · OPM change -8 pp 15% evidence | 16.9/25 ROCE 47.9% · OPM 13% 57% evidence | 9.9/20 P/E 23.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y 7.9%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 15.8 + 16.9 + 9.9 + 10 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 59Trident Techlabs LtdTECHLABS | 46.5/100Thin evidence · provisional40% evidence | 16.1/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 16.3/25 ROCE 26.7% · OPM 27% 71% evidence | 10.9/20 P/E 14.9× · PEG — 15% evidence | 3.2/20 RS sector -50.3% · RS bench -56.5% · 1Y -64%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 16.1 + 16.3 + 10.9 + 3.2 = 46.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 60Danlaw Technologies India Ltdthis page532329 | 44.9/100Thin evidence · provisional32% evidence | 16.3/35 Revenue 10.9% · PAT 14% · OPM change 1.1 pp 27% evidence | 7.7/25 ROCE 8.2% · OPM 8.9% 57% evidence | 8.7/20 P/E 115× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 44% · 1Y — 25% evidence | |
| Exact sum: 16.3 + 7.7 + 8.7 + 12.2 = 44.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 61ERP Soft Systems Ltd530909 | 44.7/100Thin evidence · provisional41% evidence | 20.2/35 Revenue 19.1% · PAT 100% · OPM change -1.1 pp 53% evidence | 8.0/25 ROCE 1.6% · OPM 1.7% 57% evidence | 8.9/20 P/E 74.9× · PEG — 15% evidence | 7.6/20 RS sector — · RS bench -47.6% · 1Y -54%0 of 12 weeks ahead to 2026-03-29 25% evidence | |
| Exact sum: 20.2 + 8 + 8.9 + 7.6 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 62Veefin Solutions LtdVEEFIN | 43.3/100Thin evidence · provisional33% evidence | 17.0/35 Revenue — · PAT — · OPM change -12.4 pp 5% evidence | 10.4/25 ROCE 6.8% · OPM 20% 57% evidence | 9.3/20 P/E 40.5× · PEG — 15% evidence | 6.6/20 RS sector -7.2% · RS bench -18.7% · 1Y -28.3%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 17 + 10.4 + 9.3 + 6.6 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 63IDream Film Infrastructure Company Ltd504375 | 41.0/100Thin evidence · provisional30% evidence | TURNING | 13.5/35 Revenue — · PAT 0% · OPM change — 29% evidence | 5.0/25 ROCE -9.2% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.5/20 RS sector — · RS bench 132.9% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 13.5 + 5 + 10 + 12.5 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 64Orient Technologies LtdORIENTTECH | 33.5/100Thin evidence · provisional45% evidence | ASLEEP | 15.5/35 Revenue — · PAT — · OPM change -5 pp 13% evidence | 2.3/25 ROCE 8.4% · OPM 2.4% 95% evidence | 9.0/20 P/E 47.3× · PEG — 15% evidence | 6.7/20 RS sector -7.1% · RS bench -17.7% · 1Y -8.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 15.5 + 2.3 + 9 + 6.7 = 33.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Danlaw Technologies India Ltd's share price today?
Danlaw Technologies India Ltd trades at ₹1,198. The company is valued at ₹584 Cr. The stock sits at 100% of its 52-week range of ₹746–₹1,198, +36.5% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 8 weeks in. — as of 7 August 2026.
What were Danlaw Technologies India Ltd's latest quarterly results?
Danlaw Technologies India Ltd reported revenue of ₹38.0 Cr and net profit of ₹1.2 Cr for the Sep 22 quarter. Revenue rose 24.5% and profit fell 30.7% year on year. Earnings per share were ₹2.99. The operating margin was 8.9%, 1.0 pp higher than a year earlier. — as of 7 August 2026.
What is Danlaw Technologies India Ltd's revenue?
Danlaw Technologies India Ltd reported revenue of ₹38.0 Cr in the Sep 22 quarter, +24.5% year on year. For the full FY22 fiscal year, revenue was ₹122 Cr (+23.2%). Over the last 10 years revenue compounded at 29.8% a year. — as of 7 August 2026.
What is Danlaw Technologies India Ltd's profit?
Danlaw Technologies India Ltd earned ₹1.2 Cr of net profit in the Sep 22 quarter, −30.7% year on year. Full-year FY22 profit was ₹4.0 Cr. The operating margin ran 8.9% in the latest quarter. — as of 7 August 2026.
What is Danlaw Technologies India Ltd's market cap?
Danlaw Technologies India Ltd's market capitalisation is ₹584 Cr at a share price of ₹1,198. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 7 August 2026.
What is Danlaw Technologies India Ltd's P/E ratio?
Danlaw Technologies India Ltd trades at a P/E of 115.0×, at the 79th percentile of its own 10-year range, against a long-run median of 56.8×. This is a comparison with the stock's own history, not a value call — as of 7 August 2026.
Does Danlaw Technologies India Ltd pay a dividend?
No — Danlaw Technologies India Ltd has recorded a dividend payout of 0% of profit in each of its last 12 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 7 August 2026.
Is Danlaw Technologies India Ltd overvalued?
On its own history, Danlaw Technologies India Ltd looks expensive against its own history: its P/E of 115.0× sits at the 79th percentile of its 10-year range (long-run median 56.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 7 August 2026.
Is Danlaw Technologies India Ltd growing?
Yes — Danlaw Technologies India Ltd is growing: latest-quarter revenue +24.5% year on year, profit −30.7%, and the margin +1.0 pp at 8.9%. The earnings engine currently reads: improving — as of 7 August 2026.
How is Danlaw Technologies India Ltd performing?
Danlaw Technologies India Ltd is in a confirmed uptrend, 8 weeks in. Its latest quarter's revenue rose 24.5% and profit fell 30.7% year on year. This describes what the data did, not a rating. — as of 7 August 2026.
Is Danlaw Technologies India Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 8 of stage 2), trading +36.5% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 7 August 2026.
Will Danlaw Technologies India Ltd's share price go up?
This page publishes no price forecast for Danlaw Technologies India Ltd. What it measures instead: the share price is ₹1,198, the price is in a confirmed uptrend 8 weeks in. Its P/E of 115.0× sits at the 79th percentile of its own 10-year range. — as of 7 August 2026.
Who owns Danlaw Technologies India Ltd?
Promoters hold 61.9% of Danlaw Technologies India Ltd, foreign institutions 0.0%, domestic institutions 0.0% and the public 37.2% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 7 August 2026.
Does Danlaw Technologies India Ltd have too much debt?
It is moderate — Danlaw Technologies India Ltd's debt-to-equity is 0.52, and operating profit covers the interest bill 3×. FY22 borrowings were ₹12.0 Cr against equity of ₹23.0 Cr. Read the returns on this page with that leverage in mind — as of 7 August 2026.
What is Danlaw Technologies India Ltd's capex?
Danlaw Technologies India Ltd spent ₹29.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY22 alone that was ₹5.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 7 August 2026.
What is Danlaw Technologies India Ltd's cash flow?
Danlaw Technologies India Ltd generated ₹6.0 Cr of operating cash flow in FY22 and ₹1.0 Cr of free cash flow after ₹5.0 Cr of capital spending. Reported profit that year was ₹4.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 7 August 2026.
Is Danlaw Technologies India Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 29% of Danlaw Technologies India Ltd's reported profit arrived as operating cash. In FY22, operating cash was ₹6.0 Cr against reported profit of ₹4.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 7 August 2026.
Where is Danlaw Technologies India Ltd in its business cycle?
Danlaw Technologies India Ltd's FY22 operating margin was 5.0%, against a 12-year band of −8.0%–18.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 8.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 7 August 2026.
What could break the Danlaw Technologies India Ltd story?
The sharpest disagreement: profits are rising, but only 29% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 7 August 2026.
Is Danlaw Technologies India Ltd a stock worth studying right now?
This is not investment advice. The machine read: Danlaw Technologies India Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 7 August 2026.